MET and renal carcinoma: A gene panel targeting ten significantly mutated genes in renal cancers (BAP1, KDM5C, MET, MTOR, PBRM1, PIK3CA, PTEN, SETD2, TP53, VHL) [35] was used with a maximal achievable sensitivity of 5 × 10− 3 mAF.